GlaukosGKOS +1.99%80 Days Inventory is 172.36 as of Mar. 2026, which is 9% above its 10-year median of 158.82. GuruFocus rates GKOS with a GF Score™ of 80/100 and a GF Value™ of $135.40 (Fairly Valued). The stock has 6 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Glaukos ranks better than 81.68% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Glaukos's Average Total Inventories for the
three
months ended in Mar. 2026 was $63.0 Mil. Glaukos's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $33.3 Mil.
Hence, Glaukos's Days Inventory for the
three
months ended in Mar. 2026 was 172.36.
The historical rank and industry rank for Glaukos's Days Inventory or its related term are showing as below:
GKOS'
s Days Inventory Range Over the Past 10 Years
Min: 98.05 Med: 158.82 Max: 264.19
Current: 98.05
During the past 13 years, Glaukos's highest Days Inventory was 264.19. The lowest was 98.05. And the median was 158.82.
GKOS's Days Inventory is ranked better than 81.68% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.86
vs GKOS: 98.05
Glaukos's Days Inventory
declined
from Mar. 2025 (219.79) to Mar. 2026 (172.36).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Glaukos's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.53.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Glaukos's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.42.
Glaukos (NYSE:GKOS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Glaukos's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Glaukos's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Glaukos Days Inventory Related Terms
Glaukos Days Inventory Historical Data
* Premium members only.
The historical data trend for Glaukos's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKOS vs LIVN, BIO, IRTC: Days Inventory Comparison
For the Medical Devices subindustry, Glaukos's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Days Inventory distribution charts can be found below:
* The bar in red indicates where Glaukos's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (GKOS) has a Days Inventory of 172.36 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Glaukos and its competitors. This is near median its historical median of 158.82. Over the past decade, Glaukos' Days Inventory has ranged from 98.05 to 264.19. According to the industry distribution chart, Glaukos ranks #144 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 18.3%.
Is Glaukos' Days Inventory too high?
Glaukos' current Days Inventory of 172.36 is near median its 10-year median of 158.82. Over the past 10 years, this metric has ranged from a low of 98.05 to a high of 264.19. The Medical Devices & Instruments industry median Days Inventory is 179.86. Glaukos' value of 172.36 is 4.2% below this industry median. Based on the distribution chart, Glaukos ranks #144 out of 786 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Glaukos has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Days Inventory compare to LIVN and BIO?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #144 out of 786 companies for Days Inventory. This places Glaukos in the top 18% of its industry — outperforming the majority of peers. The industry median Days Inventory is 179.86. Glaukos' value of 172.36 is 4.2% below this benchmark. Historically, Glaukos' own Days Inventory has ranged from 98.05 to 264.19 over the past decade. While the company's 10-year median is 158.82 vs. the industry median of 179.86, Glaukos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.86, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glaukos's current Days Inventory of 172.36 is 4.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current Days Inventory is 172.36, which is near median its own 10-year median of 158.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.40, compared to a current price of $140.50 — trading 3.8% above its estimated fair value. The current Days Inventory is 172.36, which is near median its 10-year median of 158.82 and 4.2% below the Medical Devices & Instruments industry median of 179.86. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Glaukos (GKOS), the current Days Inventory is 172.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $140.50 is trading 3.8% above its estimated GF Value™ of $135.40.
GuruFocus considers Glaukos to be Fairly Valued.
Key valuation signals for GKOS:
Days Inventory: 172.36 (near median its 10-year median of 158.82)
GF Value™: $135.40 vs. price of $140.50 (3.8% above fair value)
Industry Position: 4.2% below the Medical Devices & Instruments median (#144 of 786)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
80GF Score
Get the complete analysis for GKOS
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
